S. Holden

First name
S.
Middle name
E.
Last name
Holden
Heywood, B. R., Morgan, C. L., Berni, T. R., Summers, D. R., Jones, B. I., Jenkins-Jones, S., et al. (2023). Real-world evidence from the first online healthcare analytics platform-Livingstone. Validation of its descriptive epidemiology module. Plos Digit Health, 2, e0000310. http://doi.org/10.1371/journal.pdig.0000310
View
Holden, S. E., Jenkins-Jones, S., Poole, C. D., Morgan, C. L., Coghill, D., & Currie, C. J. (2013). The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). Child Adolesc Psychiatry Ment Health. http://doi.org/10.1186/1753-2000-7-34
View
Holden, S. E., Gale, E. A., Jenkins-Jones, S., & Currie, C. J. (2014). How many people inject insulin? UK estimates from 1991 to 2010. Diabetes Obes Metab. http://doi.org/10.1111/dom.12260
View
Morgan, C. L., Mukherjee, J., Jenkins-Jones, S., Holden, S. E., & Currie, C. J. (2014). Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab. http://doi.org/10.1111/dom.12302
View
Bannister, C. A., Holden, S. E., Jenkins-Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., et al. (2014). Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. http://doi.org/10.1111/dom.12354
View
Morgan, C. L., Mukherjee, J., Jenkins-Jones, S., Holden, S. E., & Currie, C. J. (2014). Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab. http://doi.org/10.1111/dom.12306
View
Holden, S. E., Jenkins-Jones, S., Morgan, C. L., Schernthaner, G., & Currie, C. J. (2015). Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab. http://doi.org/10.1111/dom.12412
View
Holden, S. E., Jenkins-Jones, S., & Currie, C. J. (2016). Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study. PLoS One. http://doi.org/10.1371/journal.pone.0153594
View
Holden, S. E., Jenkins-Jones, S., Morgan, C. L., Peters, J. R., Schernthaner, G., & Currie, C. J. (2017). Prevalence, glucose control and relative survival of people with Type 2 diabetes in the UK from 1991 to 2013. Diabet Med. http://doi.org/10.1111/dme.13332
View
Holden, S. E., Morgan, C. L., Qiao, Q., Jenkins-Jones, S., Berni, E. R., & Currie, C. J. (2017). Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.12916
View